Patent SG-11201900654Q-A (SG)
Title: Anti-kras-g12d t cell receptors
Inventor: TRAN ERIC
IPC: C07K14/82
Filed: 2017-07-31
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 February 2018 (08.02.2018) WIP0 I PCT olimion °nolo omolom Kill Bo 11111°1 Hs (10) International Publication Number WO 2018/026691 Al (51) International Patent Classification: C07K 14/725 (2006.01) C07K 14/82 (2006.01) (21) International Application Number: PCT/US2017/044615 (22) International Filing Date: 31 July 2017 (31.07.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/369,883 02 August 2016 (02.08.2016) US (71) Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DE- PARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; Office of Technology Transfer, National Insti- tutes of Health, 6011 Executive Boulevard, Suite 325, MSC 7660, Bethesda, Maryland 20892-7660 (US). (72) Inventors: TRAN, Eric; 1650 NE 32nd Avenue, Apt 312, Portland, Oregon 97232 (US). LU, Yong-Chen; 1620 East Jefferson, Apt 111, Rockville, Maryland 20852 (US). PASETTO, Anna; 225 Rollins Avenue, Rockville, Mary- land 20852 (US). ROBBINS, Paul F.; 7907 Glendale Road, Chevy Chase, Maryland 20815 (US). ROSEN- BERG, Steven A.; 10104 Iron Gate Road, Potomac, Mary- land 20854 (US). ZHENG, Zhili; 301 Alderwood Drive, Gaithersburg, Maryland 20878 (US). (74) Agent: LAWLEY, Stephanie M. et al.; Leydig, Voit & Mayer, Two Prudential Plaza, Suite 4900, 180 North Stet- son Avenue, Chicago, Illinois 60601 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) (54) Title: ANTI-KRAS-G12D T CELL RECEPTORS (57) : Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.